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From the Department of Pathology and the Boyer Center for
Molecular Medicine, Yale University, New Haven, Connecticut
Alzheimer’s disease threatens to become the scourge of
the 21st century. Hundreds of millions of aging people
throughout the world are at risk, but it is clear that the
disease encompasses more than just the natural aging
process. Deposits of amyloid  peptides in the brains of
demented individuals are a defining feature of the dis-
ease, yet two decades of intensive investigation, focus-
ing on reducing or removing amyloid deposits, have
failed to produce any meaningful therapeutic interven-
tions. Some researchers question whether amyloid is
the appropriate target. Others maintain that early, pre-
symptomatic intervention would be amore informative
test, and propose large-scale clinical trials in patients
who are believed to be in the earliest, and potentially
reversible, stages of the disease. This review explores the
wisdom of that approach. (Am J Pathol 2012, 180:
1762–1767; DOI: 10.1016/j.ajpath.2012.03.004)
The past 25 years have seen truly impressive gains in our
understanding of Alzheimer’s dementia,1,2 yet effective
treatments and prevention strategies are still distant
goals. Newly developed brain scanning methods, includ-
ing functional positron emission tomography (PET) scans
and structural magnetic resonance imaging (MRI), have
pointed to toxic forms of amyloid  (A) peptides as the
precipitating cause of brain dysfunction and eventual
neuronal cell death, results that appear to confirm the
primacy of the amyloid hypothesis. However, pursuing
amyloid as the most relevant therapeutic target has led to
disappointing results, most recently the failure of the
high-profile gamma secretase inhibitor semagacestat to
have any measurable success. Some question whether
the failure of anti-amyloid treatments is telling us that
amyloid is not the most relevant target. Others suggest
that treating patients with advanced disease is not a valid
test of any anti-amyloid agent. These conclusions have
1762led to multiple nationwide, multidisciplinary efforts to fo-
cus on patients with mild cognitive impairment (MCI), the
earliest detectable stage of Alzheimer’s dementia. Brain
damage in these individuals is clearly less advanced and
therefore potentially more treatable. This effort, led by the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) and
other consortia, is designed to examine whether the am-
yloid hypothesis is indeed the surest path to the devel-
opment of new therapies.3 This Review explores the sci-
ence behind this approach, some of which has been
published within the pages of The American Journal of
Pathology, and concludes that this thrust, which will re-
quire mega-millions of dollars and countless hours of
investigator and patient time, must be considered a gam-
ble, justified by the preliminary findings that support it,
but a gamble nevertheless because of so many un-
knowns that still stalk the Alzheimer’s crusade.
Background to the Amyloid Hypothesis
Alzheimer’s dementia is one of the most destructive and
feared human maladies that affects aging members of
every population in the world. First recognized a hundred
years ago on the basis of amorphous deposits of un-
known material in the brains of affected persons, we now
know that these deposits are composed in part of small
peptide fragments that are generated by proteolytic
cleavage of a large trans-membrane protein that resides
in the brain and other tissues. The functions of both the
parent protein (called APP) and the cleaved peptides
(referred to as A 40 and 42) are unknown, but there is
little doubt that both play critical roles in the workings of
the human brain. Moreover, a large body of evidence is
consistent with the view that the A peptides not only
make up the bulk of the plaques that Alzheimer de-
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Alzheimer’s dementia, making them the prime target for
therapeutic intervention. The large body of experimental
data and clinical observations that support these views is
popularly known as the Amyloid Hypothesis.
It’s always difficult, in science, to decide who did what
and when first, but George Glenner, a longstanding
member of ASIP and Chief of Experimental Pathology at
the National Institute of Arthritis and Metabolic Diseases
of the NIH in the mid-60’s, probably provided the first clue
as to the chemical nature of the plaques that Alois Alz-
heimer described in 1907. Glenner extracted a small
peptide from the blood vessels of brains from persons
with Alzheimer’s, and his analysis of this finding in 1984
led other workers in the field to identify what might be
called the “Alzheimer’s protein.” More about this protein
and the peptide that was derived from it will be described
later; but the question that readers may be asking is, Why
did it take 77 years to make this discovery? Many reasons
come to mind.
First, it should be realized that enough people had to
live beyond early middle life for the disease to develop to
the stage at which it became clinically evident as the
major health problem that we now recognize. Moreover,
the association of the disease with advancing age en-
couraged physicians to assume that it was part of the
natural aging process. We now know this was an under-
standable but incorrect assumption: Alzheimer’s demen-
tia is indeed a disease that accompanies human aging,
but it is not an inevitable consequence of it.5 Multiple
pathological processes occur as we age, and these ex-
plain why human dementia and advanced age are so
tightly coupled.
Another obstacle to the study of AD was our limited
knowledge of the human brain. Encased as it is in a
sturdy bony vault, it seemed inaccessible to the tools
scientists used to study other human tissues. Biopsies
Figure 1. A landmark discoveries. The timeline illustrates when key discov
its mutants, as well as apolipoprotein E4 allele (APOE4), presenilin (PS1 and
other techniques such as Pittsburgh compound B (PIB) scans also dramaticwere (and still largely are) not feasible, which meant thatthe tissues of the brain could only be examined by pa-
thologists after death. This led to the widespread view
(still shared by many physicians) that a definitive diag-
nosis of AD could be made only by autopsy. Autopsy
studies are rightly considered the gold standard for de-
termining cause of death and the extent of a disease
process, but they have their limitations. For one thing,
they only tell what was going on at the time of death, and
although they reveal much about the end stage of a
complex process such as AD, one can only guess as to
what may have happened during the lifetime of the pa-
tient. In the case of AD, this limitation is glaring, because
we now know that AD probably begins—in some form still
to be revealed—years before symptoms appear.
What propelled the AD field forward was the develop-
ment of recombinant DNA technology. Building on the
findings of Glenner, it was possible to identify the larger
protein from which the peptide was derived, and this led
to a watershed of discoveries. These are highlighted in
Figure 1. Several points need emphasizing. Once the
amyloid peptide was positively identified, the gene for the
amyloid precursor protein (APP) was relatively quickly
(for that era) deduced, opening the floodgates to a torrent
of discoveries. Within a little more than a decade, almost
everything that we know about the role of amyloid in AD
was revealed. Mutant forms of APP and the gamma
secretases showed that defective genes could indeed
contribute to disease, but their rarity meant that, for most
AD patients (95%) who lacked these defective genes,
other causes had to be determined. The APOE4 allele of
apolipoprotein E was found to predict earlier-onset forms
of sporadic AD, but this finding was reported two de-
cades ago, and we still have no clear idea how these
protein variants contribute to disease. Recombinant DNA
technology allowed investigators to develop animal mod-
els that appeared to mirror the human form of AD; but
such animals usually generated far more amyloid in their
our understanding of A were made, such as discovery of the APP gene and
tants, and A oligomeric ligands (ADDLs). The advent of animal models and
roved the study of Alzheimer’s disease.eries inbrains than most humans ever have, leading many to
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that can be used to test new forms of therapy.
In 1999 it was discovered that antibodies to the amy-
loid peptide could be used to flush out amyloid from the
brains of genetically engineered mice.6 This was an ex-
traordinarily important discovery that has led to a multi-
tude of clinical trials that are now in progress. Another
pivotal advance was the introduction of amyloid-binding
dyes that were able to detect amyloid in living persons.
Pittsburgh compound B (PIB) scans, first described in
2002, provided the ability to monitor the progression of
amyloid deposits in individuals who have not yet reached
full-blown dementia.
Collectively, this huge body of both experimental and
clinical information supports the idea that A peptides
contribute significantly to the pathogenesis of Alzhei-
mer’s disease and its accompanying dementia. That
stated, it is still a mystery how the two are causally re-
lated. Among the many unknowns are when Alzheimer’s
disease first starts, and even how it starts. Nor do we
have any idea what the triggering elements are. Two
features of the disease are generally agreed on: AD prob-
ably starts years before clinical symptoms are evident;
and, because it takes so long to develop into clinical
disease, it must be a very slow disease process, or, more
likely, several different processes that act in concert.
These two features—its early undetected onset and the
long pathogenic course—have made it difficult to repro-
duce the disease in experimental animals. This accounts
in part for so much uncertainty about this disease despite
the vast research effort that has already been expended.
This great uncertainty has fueled efforts to find ways to
identify persons carrying AD-specific biomarkers who
might be in the early stages of the disease, long before
symptoms appear, and hopefully before significant, pos-
sibly irreversible damage has occurred.
The Search for Biomarkers
Biomarkers are objectively measured ways to detect a
disease process or the predisposition to disease in a
living person. An elevated white blood cell count signals
infection, and high serum cholesterol correlates with the
predisposition to atherosclerosis. The practice of clinical
medicine would grind to a halt without these essential
diagnostic tools. Unfortunately, there is no simple, reli-
able, and reproducible blood test for any aspect of Alz-
heimer’s dementia. Many attempts to develop one have
been made, but none has succeeded.
Although attempts to measure A levels in the blood
have so far not proved useful, measurements of cerebro-
spinal fluid (CSF) have produced an unexpected sur-
prise. Levels of A 42 are lower in AD patients than in
matched controls; and when they are correlated with
positive PIB, a stain for brain amyloid, patients with MCI
can be identified. By correlating imaging studies with
CSF analysis, it is therefore possible for the first time to
identify MCI patients by objective measurement alone.
This represented a great advance, as it offered the pos-
sibility of evaluating new therapies using objective mea-surements alone. Jack and colleagues7 further proposed
that by correlating five different biomarkers, including
three by imaging (PET-amyloid, FDG-PET, and structural
MRI) and two by CSF analysis (A 42 and P-tau), it might
be possible to predict the stage of disease in any given
patient. This analysis predicts that biomarkers of A de-
position become abnormal first, long before neurodegen-
eration and clinical symptoms appear. In contrast, FDG-
PET, CSF Tau, and MRI-detectable atrophy become
abnormal in the MCI stage, when symptoms of the dis-
ease are already evident. These findings and others like
them have led to important policy decisions within the AD
investigator community.
Should Reduction of Amyloid Deposits in
Brains of Individuals Suffering from MCI Be a
High-Priority Goal?
There is a widespread consensus among AD investiga-
tors who have participated in the ADNI program that
therapies that reduce A accumulations by decreasing
production, by increasing turnover, or by antibody re-
moval should be tested first in MCI patients in an attempt
to arrest the progression of MCI to advanced dementia.
This is based on the following assumptions: i) biomarkers
and brain scans can be used to identify MCI patients and
to follow their progression to frank dementia; ii) MCI pa-
tients will usually progress to clinical dementia over the
course of several years; and iii) amyloid-related peptides
accumulate in the brain during the MCI stage and are
presumed to be pathogenic.
It makes sense to continue to support the expansion
of the ADNI program by adding to these studies the
testing of new therapies, realizing that existing animal
models that focus on amyloid overload have not
proved to be reliable ways to test new therapies. Al-
though many recent attempts to treat patients by re-
ducing amyloid levels in the dementia stage of the
disease have not succeeded, one assumes that there
is a better chance of preserving existing neuronal func-
tions in MCI patients than in those with advanced de-
mentia. An added advantage is the ability to monitor
treatment efficacy with objective tests.
Remaining Unknowns
While supporting this program, it is useful to acknowl-
edge the imposing number of questions regarding the
pathogenesis of AD that, if they remain unanswered, will
continue to constrain our ability to design and test the
most appropriate therapies and to formulate rational
guidelines for prevention.
1. When, where, and how do the earliest lesions that
lead to MCI develop?
2. How do A peptides, in whatever form, damage
neurons?
3. What is the physiological function of A peptides?
4. How do neurofibrillary tangles contribute to dis-ease?
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onset?
6. Is inflammation a factor?
7. Does blood vessel damage contribute to amyloid
dysregulation?
8. What are the most effective preventive measures?
It is hardly surprising that we have yet to identify the
earliest lesions that eventually lead to neuronal degener-
ation and clinical dementia. As is the case when studying
other chronic diseases, looking solely at the late stages of
a disease may be misleading, and this is particularly true
if we lack suitable animal models. All of the existing
murine models that are routinely studied as AD proxies
rely on overproduction of amyloid A peptides. Since
significant amounts of amyloid accumulate late in the
human disease, it seems likely that other processes, such
as oxidative damage and/or inflammatory reactions, may
precede amyloid dysregulation, as many AD investiga-
tors have previously suggested (see references in
Marchesi8). We must also consider the possibility that
large-scale amyloid accumulations are a late event in
human AD, triggered by as-yet-unknown processes. In
this case, anti-amyloid therapies may not be effective
ways to treat MCI.
Another perplexing aspect of the AD field is the sur-
prising lack of any consensus as to what form of A
peptides are toxic to neurons in the living brain. Part of
the problem is the quixotic nature of the A peptides
themselves. Are they critically involved in synaptic activ-
ity and neurotransmission, as recent studies suggest,9 or
are they nuisance degradation products prone to clump
together and clog up the interstitial spaces? Since ele-
vated levels of A production are found only in patients
with rare mutations, reduced clearance of A rather than
overproduction is considered the most likely cause of
amyloid accumulation in advanced disease and is the
basis for a vigorous effort to reduce their level in the
brain. Precisely why they accumulate is still unclear; but
reducing them, by whatever means, is the stated goal,
even though we must also consider the possibility that
lowering the level of a normally functioning peptide by
blocking its synthesis, or by immune-mediated clear-
ance, might, in the end, impair normal neuronal functions
and would therefore be an undesirable side effect. Ide-
ally, targeting the toxic form of Amakes the most sense,
but this still remains an elusive goal. Much has been
made of the tendency of A peptides to aggregate at
high concentrations in vitro. Oligomeric forms of widely
varying sizes have been identified as putative toxic
forms; but their mode of action remains unknown, and
they are technically demanding to study. At this point
they do not seem like promising therapeutic targets.
Neurofibrillary tangles are as omnipresent in AD brains
as amyloid plaques, and many have suggested that their
presence correlates more faithfully with dementia than
the plaques themselves. How and why they develop, and
how they contribute to the pathogenic cascade, is just as
mysterious as amyloid’s contribution to neurotoxicity. This
is not to deny their importance, but only to stress thedifficulty that we have in evaluating their effects without a
suitable animal model.
How does oxidative damage contribute to AD? There is
abundant, indeed overwhelming, evidence that reactive
oxygen and reactive nitrogen species have the ability to
modify every molecular species in the human brain, and
are especially prominent in AD brains. Oxidative changes
in membrane lipids are widely recognized; however, less
attention has been focused on oxidized nucleic acids,
which is surprising, as modified DNA and RNA have the
potential to generate mutant proteins that could play a
pathogenic role.10 Inflammatory reactions and damaged
small blood vessels were once thought to play major
pathogenic roles in early AD, but their significance has
been eclipsed by the overwhelming logic of the amyloid
cascade. The inability of anti-inflammatory agents to
modify advanced disease also diminished enthusiasm for
an inflammatory mechanism. However, now that we have
discovered that anti-amyloid agents are also unable to
modify advanced disease, we may have to reconsider
anti-inflammatory approaches as therapies for the pre-
clinical stage. Again, the lack of suitable animal models
that reflect inflammatory and vascular damage of the
brain hampers our ability to test potential anti-oxidative
damage and anti-inflammatory agents.
Conclusions
It is a good idea and sound public policy to focus on
treating individuals who suffer from MCI. Such individuals
can be identified with reliable biomarkers, their progres-
sion to frank dementia is predictable, and their response
to therapy can be evaluated by objective measurements.
However, we must be ready for some surprises. Although
amyloid is likely to contribute to advanced disease, its
pathogenic potential may rely on as-yet-unidentified fac-
tors that could compromise agents or treatments that act
on amyloid alone. Moreover, although amyloid deposits
are a prominent feature of both MCI and advanced de-
mentia, other pathogenic processes may act in the early
stages of the disease, and they may progress to neuronal
injury despite the reduction or absence of amyloid. Ar-
resting disease progression is a desirable goal worth
pursuing at all costs—but the gold standard will be pre-
vention. This will require answers to the questions stated
above.
Postscript: AJP’s Contributions to Our
Understanding of AD Pathology
It is fitting to commemorate ASIP’s centennial with a dis-
cussion of the present state of Alzheimer’s research, as it
is generally acknowledged that the modern era of AD
research was launched by George Glenner. Glenner’s
first study of murine amyloidosis was published in The
American Journal of Pathology in 1972.11
Many important contributions to AD research have
been published in AJP beginning in 1964 with the first
ultrastructural analysis of Alzheimer’s presenile demen-
tia,12 followed in 1973 by the finding that Alzheimer’s
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lated.13 Glenner’s findings led to the discovery of the
gene for the amyloid precursor protein (APP), and this
unleashed a cascade of discoveries including the link
between brain amyloid, blood vessel amyloid, and de-
mentia14 and the discovery that Alzheimer’s neurofibril-
lary tangles were associated with the microtubule-asso-
ciated protein tau.15 In 1990 it was claimed that diffuse
amyloid plaques were not necessarily related to synaptic
loss and the accompanying dementia,16 a prophetic sug-
gestion that was ultimately confirmed in later years.
The 1990s saw a range of significant publications in
AJP that included a description of a hereditary form of
cerebral angiopathy,17 an analysis of paired helical tau
filaments,18 the link between apolipoprotein E4 and se-
nile plaques in aged rhesus monkeys,19 and the finding
that the cell cycle regulators P16 and CDK4 might be
expressed in AD brains 20. Three AJP publications that
foresaw changes in the way that present-day investiga-
tors view the AD problem were the analysis of interstitial
fluid drainage pathways as a way to explain A accumu-
lations in AD brains 21, the connection between brain
trauma and amyloid–induced neuron death,22 and the
potential role of the complement system in the pathogen-
esis of AD23 that has led to an awakened interest in
inflammation as a pathogenic mechanism.
The last decade has seen a dramatic increase in pub-
lications exploring blood vessels as potential pathogenic
targets that lead to dementia. Germ line mutations in APP
were found to develop cerebral amyloid angiopathy,24
mutants of APP that generated vasculotropic A peptides
and induce vascular degeneration and euroinflamation25;
the finding that dense-core amyloid plaques in mutant
mice were centered on blood vessel walls26; and the idea
that brain endothelial cells synthesize neurotoxic throm-
bin in AD brains 27. This past year has seen two reports
that focus on inflammation as a primary pathogenic
cause: one stresses infection in transgenic mice,28 and
the other reports that neurovascular defects and inflam-
mation precede the toxic effects of -mediated neurode-
generation.29
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